AgilVax Email Format
Biotechnology ResearchNew Mexico, United States11-50 Employees
Agilvax is a biotechnology company focused on developing targeted antibody-based therapies for cancer, with its AX09 program aimed at metastatic breast cancer. The program also explores adjunctive use for metastatic triple-negative breast cancer, reflecting a broader focus within breast cancer subtypes. The company is based in Albuquerque, New Mexico, and operates as a small to mid-sized firm within the biotechnology research sector. The company has disclosed collaborations in its history, including a 2016 collaboration with Leidos on a malaria vaccine program. The organization positions itself as a research-driven enterprise in oncology, pursuing novel antibody-based therapeutics for cancer.